Advanced GC patients with SRC who developed peritoneal recurrence tended to have more PD-L1 expression, while advanced GC patients without SRC who had liver metastasis are likely to have PI3K/AKT pathway mutations, TP53 mutations and PD-L1 expression. This evidence concerns the gene PIK3CA and gastric cancer.